Centrepoint Alliance Limited (ASX:CAF)

Inozyme Pharma Revenue

Centrepoint Alliance had revenue of 159.95M AUD in the half year ending December 31, 2024, with 19.08% growth. This brings the company's revenue in the last twelve months to 307.70M, up 10.62% year-over-year. In the fiscal year ending June 30, 2024, Centrepoint Alliance had annual revenue of 288.41M with 6.10% growth.

• Revenue (ttm): 307.70M
• Revenue Growth: +10.62%
• P/S Ratio: 0.28
• Revenue / Employee: 1.65M
• Employees: 187
• Market Cap: 85.52M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2024	288.41M	16.59M	6.10%
Jun 30, 2023	271.82M	43.49M	19.05%
Jun 30, 2022	228.34M	89.46M	64.42%
Jun 30, 2021	138.88M	7.94M	6.06%
Jun 30, 2020	130.94M	13.44M	11.44%